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Introduction: Heat shock protein 90 (Hsp90) is an abundant mo-
lecular chaperone that mediates the maturation and stability of a
variety of proteins associated with the promotion of cell growth and
survival. Inhibition of Hsp90 function leads to proteasomal degra-
dation of its mis-folded client proteins. Recently, Hsp90 has
emerged as being of prime importance to the growth and survival of
cancer cells and its inhibitors have already been used in phase I and
II clinical trials.
Methods: We investigated how 17-allylamino-17-demethoxy-
geldanamycin (17-AAG), a small molecule inhibitor of Hsp90, is
implicated in human malignant pleural mesothelioma (MM).
Results: We found that 17-AAG led to significant G1 or G2/M cell
cycle arrest, inhibition of cell proliferation, and decrease of AKT,
AKT1, and survivin expression in all human malignant pleural
mesothelioma cell lines examined. We also observed significant
apoptosis induction in all MM cell lines treated with 17-AAG.
Furthermore, 17-AAG induced apoptosis in freshly cultured primary
MM cells and caused signaling changes identical to those in 17-
AAG treated MM cell lines.
Conclusion: These results suggest that Hsp90 is strongly associated
with the growth and survival of MM and that inhibition of Hsp90
may have therapeutic potential in the treatment of MM.
Key Words: Hsp90, 17-AAG, Cell cycle arrest, Apoptosis, Me-
sothelioma.
(J Thorac Oncol. 2008;3: 1089–1095)
Malignant pleural mesothelioma1 (MM) is an asbestos-related malignancy characterized by rapidly progress-
ing, diffuse, local growths, late metastases, and poor prog-
noses.2 Approximately 3000 patients are diagnosed with MM
each year in the United States, and the incidences are ex-
pected to steadily rise over the next two decades.3 Unfortu-
nately, the prognosis even after standard therapies (surgery,
chemotherapy, and radiation) remains dismal, and most pa-
tients die within 12 to 15 months of their first symptoms if left
untreated.4 New therapies based on improved understanding
of the molecular mechanisms behind MM are, therefore,
imperative.
Heat shock protein 90 (Hsp90) is a molecular chaper-
one that participates in the folding, assembly, maturation, and
stabilization of a variety of proteins.5 Hsp90 is ubiquitously
expressed at 2- to 10-fold higher levels in tumor cells than in
their normal counterparts. Hsp90 is present entirely in mul-
tichaperone complexes with high adenosine triphosphatase
activity in tumor tissues, whereas in normal tissues it is in a
latent, uncomplexed state.6,7 Thus, Hsp90 may be critically
important for tumor cell growth and survival. Inhibition of
Hsp90 function disrupts the complex and leads to degradation
of client proteins in a proteasome-dependent manner.8
A small molecule inhibitor of Hsp90, 17-allylamino-
17-demethoxygeldanamycin (17-AAG) is a less-toxic deriv-
ative of the ansamycin antibiotic geldanamycin.8 It directly
binds to the adenosine triphosphate/adenosine diphosphate-
binding pocket, thereby replacing the nucleotide and inhibit-
ing Hsp90 function as a molecular chaperone for its client
proteins.9 It has been shown that 17-AAG has a 100-fold
higher binding affinity in tumor cells than that in normal
cells, and it has antitumor activity in several human xenograft
models.7,10,11 This promising drug is currently completing
multi-institution phase I clinical trials, and phase II trials are
being planned and performed.1,6,12–18
AKT is a serine/threonine kinase that lies downstream
of phosphatidylinositol 3-kinase and mediates a wide variety
of biological responses to epidermal growth factor receptor
and other growth factor receptors19,20. The AKT signaling
pathway is involved in the regulation of a large variety of
cellular processes including growth, cell cycle, death, and sur-
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vival. It has been demonstrated that AKT is constitutively active
in many types of human cancers and that aberrant activation of
the phosphatidylinositol 3-kinase/AKT survival pathway leads
to an increase in antiapoptotic signals19 that inhibit the effec-
tiveness of conventional chemotherapy.21 Recent results show
that AKT is active in MM and relies on Hsp90 for its stability
and activity.5,11,22–24
Survivin is a structurally unique member of the inhib-
itor of apoptosis proteins family, and is involved in the
control of mitotic progression and inhibition of apoptosis.25
Several retrospective studies have found that survivin is a
reliable marker of aggressive and unfavorable disease pro-
gression in various malignancies and is associated with ab-
breviated overall survival.25 Survivin is found highly overex-
pressed in MM26 and is also a client protein of Hsp90.27
Taken together, these reports suggest that inhibition of
Hsp90 function may have implications in the treatment of
refractory MM. In the present study, we demonstrate a possible
therapeutic role of 17-AAG in the treatment of MM cells.
MATERIALS AND METHODS
Cell Lines and Tissue Samples
Human mesothelioma cell lines were obtained from the
following sources: H2052, H28, and 211H from American
Type Culture Collection (Manassas, VA), H290 from Na-
tional Institutes of Health (Frederick, MD), and REN through
a generous gift from Dr. Steven Albelda (University of
Pennsylvania, Philadelphia, PA). All cells were cultured in
RPMI 1640 supplemented with 10% fetal bovine serum at
37°C in a humidified incubator with 5% CO2.
Fresh MM tissue samples obtained directly from sur-
gical resection were cut into pieces (1–2 mm in diameter) and
digested with Triple Enzyme Solution containing collage-
nase, deoxyribonuclease, and hyaluronidase (Sigma, St.
Louis, MO) at room temperature for 16 hours according to
National Cancer Institute laboratory protocol. Single cells
from the digestion were spun down and the cell pellets were
washed twice using Hanks Balanced Salt Solution (Invitro-
gen, Carlsbad, CA). The cells were resuspended in RPMI
1640 media supplemented with 10% fetal bovine serum,
penicillin (100 IU/ml) and streptomycin (100 g/ml), and
cultured in 6-well plates at 37°C in a humidified incubator
with 5% CO2 until ready for treatment. Other fresh MM
tissue samples were immediately snap-frozen in liquid nitro-
gen. They were preserved at 170°C in a liquid nitrogen
freezer before use.
Drug
A 17-AAG was purchased from Sigma (St. Louis,
MO). Stock solution was prepared in 100% DMSO and
stored at 20°C. The drug was diluted in fresh media before
each experiment.
Cell Cycle Analysis
Cells were plated on six-well plates, incubated for 24
hours, and then treated with DMSO, 1 m 17-AAG, or 2 m
17-AAG. For flow cytometry, cells were trypsinized and fixed in
70% ethanol at 20°C, washed and stained with 30 g/ml
propidium iodide (PI) (Sigma, St. Louis, MO), and then incu-
bated with 10 g/ml RNase (Roche, Indianapolis, IN) for 1
hour at room temperature. Cells were evaluated on a FACS-
can machine (Becton Dickinson, Franklin Lake, NJ) and the
data analyzed with the ModFit LT 3.1 Mac software for
modeling cell cycle distribution. Experiments were per-
formed in triplicate, and data were expressed as mean  SD.
Cell Proliferation Assay
Cell proliferation assays were performed using the
CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega, Madison, WI) according to the manufacturer’s
protocol. Cells were plated at 1000 cells/well in 100 l of
media in 96-well plates. After 24 hours, the cells were
treated with DMSO or 17-AAG (2 m) and incubated for
48 hours. Methanethoiosulfonate/phenazine methosulfate
solution (20 l/well) was added and incubated for 2 hours
at 37°C in a humid incubator with 5% CO2. Absorbance
was read at 490 nm using a microplate reader. Cell via-
bility was calculated according to the following formula.
Cell viability  OD490 (DMSO treated cells or 17-AAG
treated cells)/OD490 (nontreated cells).
Western Blotting
Whole cell lysates of MM cell lines and primary tissue
cultures were obtained using CytoBuster Protein Extraction
Reagent (Novagen, Madison, WI). Protein samples were
separated on 4 to 15% gradient sodium dodecyl sulfate-
polyacrylamide gels and transferred to Immobilion-P (Milli-
pore, Bedford, MA) membranes. Antigen-antibody com-
plexes were detected by the enhanced chemiluminescence
blotting analysis system (Amersham Pharmacia Biotech, Pis-
cataway, NJ). The following primary antibodies were used:
Hsp90 and Hsp70 (Stressgen, Victoria, BC, Canada); AKT,
cleaved PARP (Cell Signaling Technology, Beverly, MA),
AKT1, survivin (Santa Cruz Biotechnology, Santa Cruz,
CA), p53 and -Actin (Sigma Chemical Co., St Louis, MO).
Apoptosis Analysis
Following drug treatment, cells were harvested by
trypsinization and stained using an Annexin V-FITC Apopto-
sis kit (BioSource, Camarillo, CA) according to the manu-
facturer’s protocol. Stained cells were immediately analyzed
by flow cytometry (FACScan; Becton Dickinson, Franklin
Lake, NJ). Early apoptotic cells were characterized by ex-
posed phosphatidylserine bound to Annexin V-FITC but not
to propidium iodide. Cells in necrotic or late apoptotic stages
were labeled both with Annexin V-FITC and with PI. Exper-
iments were performed in triplicate and a total of 20,000 cells
were analyzed in each individual experiment.
Statistical Analysis
The data presented represent mean values (SD). Sta-
tistical comparisons were made with a two-sided Student t
test. A p value of less than 0.05 was considered to be
statistically significant. Asterisks (*) represent statistical sig-
nificance (*p  0.05; **p  0.01).
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RESULTS
Expression of Hsp90 in MM Cell Lines and
Primary MM Tissue Samples
It has been reported that Hsp90 is one of the most
abundant cellular proteins, accounting for about 1 to 2% of
total protein under nonstressed conditions.5 To confirm the
expression of Hsp90 in MM, we performed Western blotting
analysis using 13 MM tissue samples and 5 MM cell lines and
found that all MM tissue samples and cell lines that we
examined expressed Hsp90 protein (Figures 1A, B).
A 17-AAG Leads to G1 or G2/M Cell Cycle
Arrest and Inhibits Cell Proliferation in
MM Cells
Hsp90 has been observed to play an important role in
human cancer cells. For example, inhibition of Hsp90 by
17-AAG leads to G1 or G2/M cell cycle arrest in gynecologic
cancer cells and breast cancer cells.5,28,29 To examine the role
of Hsp90 function in MM, we first treated five MM cell lines
for 24 hours using either DMSO, 1 m 17-AAG, or 2 m
17-AAG, and then performed cell cycle analysis. We found
significant G0/G1 arrest in H2052 and 211H cells after
treatment with 17-AAG (Figure 2A). Specifically, in H2052
cells significant accumulation of cells in G1 phase was
observed in both the 1 m and the 2 m 17-AAG treated
cells as opposed to in the DMSO treated ones (1 m: p 
0.03, 2 m: p  0.01). In 211H cells, significant accumula-
tion of cells in G1 phase was observed in 2 m 17-AAG
treated cells compared with the DMSO treated ones (1 m:
p  0.06, 2 m: p  0.01). No obvious changes in accumu-
lation at G2/M phases after 17-AAG treatment were observed
in either H2052 or 211H cell lines (data not shown).
On the other hand, we observed significant accumula-
tion of cells in G2/M phases in both the 1 m and the 2 m
17-AAG treated cells as opposed to in the DMSO treated
cells in several other MM cell lines; H28 (1 m: p  0.01, 2
m: p  0.01), REN (1 m: p  0.01, 2 m: p  0.04), and
H290 (1 m: p 0.01, 2 m: p 0.01) (Figure 2B). In these
latter cell lines, no obvious changes in accumulation at
G1/G0 phases were observed following 17-AAG treatment
(data not shown).
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FIGURE 1. Western analysis of the Hsp90 expression in 13
MM tissue samples (A) and in 5 MM cell lines (B). -Actin
served as loading control.
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To confirm cell cycle arrest after 17-AAG treatment in
MM cell lines, we performed cell proliferation assays. Across
all cell lines, after 48 hours of treatment we observed signif-
icant inhibition of cell proliferation in 17-AAG (2 m)
treated cells compared with DMSO treated ones (H2052: p
0.02, other cell lines: p  0.01) (Figure 3A). Our results
indicate that cell cycle arrest correlates with the growth
suppression of these MM cells.
The Hsp70 and Hsp90 chaperone systems are linked by
the adaptor protein HOP/p60, which interacts with the C-
terminals of both Hsp70 and Hsp90 via its tetra-copeptide
repeat domain.30 Increased levels of Hsp90 and Hsp70 are an
indication of cellular stress response, and inhibition of Hsp90
function has been previously reported to increase Hsp90 and
Hsp70 levels in various cancer cell types.14,16,18,31 Consis-
tently, we found that 17-AAG treatment (2 m for 24 hours)
also increased expression levels of Hsp90 and Hsp70 in all
MM cell lines (Figure 3B). The AKT pathway plays a crucial
role in cell growth and survival.20 To analyze whether 17-
AAG suppresses cell growth by interfering with this pathway,
we also analyzed AKT and AKT1 expression levels after
17-AAG treatment (Figure 3B) and found that expression of
both AKT and AKT1 decreased after 17-AAG treatment in
all MM cell lines. Taken together our results revealed that in
MM, decreased cell viability was associated with up-regu-
lated expression of Hsp90 and Hsp70, and that inhibition of
Hsp90 function by 17-AAG suppressed cell proliferation
through AKT-dependent cell cycle arrest.
A 17-AAG-Induced Apoptosis in MM Cell Lines
Reduced levels of PI3-AKT pathway-associated pro-
teins increase apoptosis.20 To determine whether 17-AAG
leads to apoptosis in addition to cell growth suppression in
MM cells, the AnnexinV apoptosis assay was used to exam-
ine MM cells after treatment with 1 and 2 m 17-AAG. After
2 days of treatment, significant apoptosis induction was ob-
served in three MM cell lines (REN, 1m: p 0.01, 2m: p
0.01; H290, 1 m: p  0.02, 2 m: p  0.01; H28, 2 m,
p  0.03) (Figure 4A). In H2052 and 211H cells, significant
apoptosis induction was observed after 3 days of treatment
with 2 m 17-AAG (H2052: p  0.01; 211H: p  0.02).
Consistently, we found that after 2 m 17-AAG treatment for
2 days, the level of cleaved poly (ADP-ribose) polymerase
protein (active form) was increased in four MM cell lines (H28,
REN, and H290) (Figure 4B). In H2052 and 211H, the expres-
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FIGURE 3. Proliferation assay of MM cells after 17-AAG
treatments. (A) MTT assay after 48 hours treatment with 17-
AAG. A 17-AAG inhibits growth of MM cells. Gray: OD490
(DMSO treated cells)/OD490 (nontreated cells); black:
OD490 (17-AAG treated cells)/OD490 (nontreated cells). (B)
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sion of cleaved PARP protein increased after 3 days of treatment
with 2 m 17-AAG. Furthermore, the expression level of survivin,
an apoptosis inhibitor, decreased in all MM cell lines after 2 m
17-AAG treatment for 2 days (Figure 4B).
A 17-AAG-Induced Apoptosis in Primary
Cultured MM Tissues
We next investigated the efficacy of 17-AAG in the
treatment of primary MM tissue cultures. After 3 days,
significant apoptosis was observed in 17-AAG (2 m) treated
cells compared with those treated with DMSO alone (p 
0.04) (Figure 5A). Consistently, we observed increased ex-
pression of cleaved PARP and decreased expression of sur-
vivin (Figure 5B). Moreover, in line with our observations in
17-AAG treated MM cell lines, we observed increased levels
of Hsp90 and Hsp70 as well as decreased levels of AKT,
suggesting that the 17-AAG inhibitory mechanism is similar
in both MM cell lines and primary MM cultures (Figure 5B).
Taken together, these results suggest that 17-AAG may have
a therapeutic role in the treatment of MM.
DISCUSSION
Chemotherapy, radiotherapy, and surgery have long
been standard treatments for MM. Several MM chemother-
apy regimens such as Pemetrexed plus Cisplatin or Gemcit-
abine plus Cisplatin are valuable for palliation. These treat-
ments not only decrease tumor burden but also relieve
symptoms such as pain and breathlessness. However, no
chemotherapy regimen for mesothelioma has yet proven
wholly curative. Clinical trials show objective response rates
of 41 to 48%, median survivals are less than 12 months, and
the therapies themselves are still controversial.32–35 Radio-
therapy has been used in MM for about 30 years but the
results have been largely disappointing. Although the opera-
tive mortality rate is now around 6% for the procedure,32,36,37
extrapleural pneumonectomies are performed in select patients
at specialized centers to completely remove all MM; however,
adjuvant therapy after surgery still remains necessary.
Recently, molecular target medicines, such as imanitib
(2-phenylaminopyrimidine tyrosine kinase inhibitor) and ge-
finitib (EGFR inhibitor) have also been investigated in MM
patients. Nevertheless, these drugs do not appear to be effective
against MM according to early studies.38,39 Therefore, it is vital
that more effective therapies against MM are developed.
Heat shock proteins are a group of chaperones impor-
tant in maintaining the stability and function of their client
proteins. Hsp90 is one of the most abundant heat shock
proteins found in human cells. Nevertheless, Hsp90 is distinct
from other heat shock proteins in that it does not participate
in general protein folding. Instead, it acts by regulating the
stability and function of several signal transduction proteins,
and plays an important role in biological processes that include
hormone signaling, cell cycle control, and development.5–7
A 17-AAG is currently in clinical trials as a drug
against a variety of solid tumors1,13–18,40,41 and shows a time-
and dose-dependent growth inhibition of Hodgkin lymphoma
cell lines31 as well. There are extensive preclinical data both
in vitro and in vivo suggesting that inhibition of Hsp90 is a
rational therapeutic approach to cancer, either alone or in
combination with standard chemotherapeutic drugs. Several
investigators have also found that 17-AAG can be used to
sensitize cancer cells to radiation therapy.42,43 Nevertheless,
studies of Hsp90 in MM have been limited.
In our study, we investigated cell cycle arrest and
suppression of cell growth after 17-AAG treatment in MM
cell lines. Our results revealed that Hsp90 function is strongly
associated with cell growth in MM. Previous studies showed
that 17-AAG led to G1 arrest in retinoblastoma (Rb)-positive
breast cancer cell lines and to G2/M arrest in Rb-negative
ones.29 In cervical carcinoma cells, another Hsp90 inhibi-
tor17-(dimethylaminoethylamino)-17-demethoxygeldanamy-
cin (17-DMAG) induced G2/M arrest through AKT regula-
tion.44 All MM cell lines examined in our study were found
to be Rb-positive45 (data not shown). Nevertheless, 17-AAG
was observed to induce both G1 arrest (in H2052 and 211H)
and G2/M arrest (in H28, REN, and H290) (Figure 2). These
results suggest that 17-AAG can induce either G1 arrest or
G2/M arrest through suppression of the AKT pathway in
Rb-positive MM cells. Our interpretation is that Hsp90 chap-
erones a number of different cell cycle regulatory proteins,
including those involved in both G0-G1 and G2-M entries in
MM cells. The final predominant effect on the cell cycle may
depend on the net effect on all these proteins.44,46 Notably,
about 50% of the untreated H2052 and 211H cells were also
in G1 phase (Figure 2A). This is possibly due to cell-cell
contact inhibition47 resulting from their fast-growing nature.
A 17-AAG not only suppresses cell growth but also
induces apoptosis in a variety of cancer cells.8 Our results
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reveal that 17-AAG leads to apoptosis as well as to decreased
expression levels of AKT and survivin in MM. AKT and
survivin have antiapoptotic functions and are active or over-
expressed in many cancer cells.25,48 Georgakis et al.31 showed
that 17-AAG causes AKT down-regulation and Hsp70 up-
regulation in Hodgkin lymphoma cell lines. In addition, Sain
et al.48 suggested that 17-AAG causes p-AKT and AKT
down-regulation and Hsp70 up-regulation in ovarian carci-
noma cell lines. It has also been reported that inhibition of
AKT leads to suppression of cell growth and apoptosis in
MM.22,23 In addition, down-regulation of survivin, which
predicts poor prognosis,49,50 induces apoptosis in MM.26
These reports are consistent with our results and support the
observation that 17-AAG leads to apoptosis in MM.
In summary, we demonstrated that 17-AAG, an Hsp90
inhibitor, leads to G1 or G2/M cell cycle arrest, to suppres-
sion of cell growth, and to apoptosis resulting from decreased
levels of AKT and survivin in human MM cell lines. We also
demonstrated that this small molecule induces apoptosis in
MM primary cultures (Figure 5). Our findings suggest that
inhibition of Hsp90 function is a promising therapeutic target
for a highly aggressive and inexorably fatal cancer.
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